(BLFS) BioLife Solutions - Overview
Stock: Biopreservation Media, Freeze Media, Thawing Device, Transport Container
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 54.4% |
| Relative Tail Risk | -7.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.14 |
| Alpha | -35.38 |
| Character TTM | |
|---|---|
| Beta | 1.319 |
| Beta Downside | 1.023 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.06% |
| CAGR/Max DD | -0.01 |
Description: BLFS BioLife Solutions January 20, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) designs, manufactures, and sells biopreservation and bioproduction products that support the cell and gene therapy (CGT) ecosystem across the U.S., Europe, the Middle East, Africa, and other international markets. Its portfolio includes proprietary media such as HypoThermosol FRS and CryoStor Freeze Media, expansion reagents like human platelet lysates, closed-system vials (CellSeal), automated thawing platforms (ThawSTAR), and cloud-connected Evo shipping containers for temperature-sensitive biologics.
Key performance indicators highlight the company’s growth trajectory: BLFS reported a 22 % year-over-year increase in revenue for Q4 2024, driven largely by expanding demand for CGT-compatible media; cash and short-term investments stood at $115 million, providing runway for R&D and commercial scaling; and the Evo container fleet now supports over 1,200 shipments per month, reflecting strong adoption of its IoT-enabled logistics solution.
The CGT sector is projected to grow at a compound annual growth rate of roughly 15 % through 2030, creating a secular tailwind for suppliers like BioLife that address cold-chain integrity and cell-culture efficiency; however, the company remains sensitive to reimbursement policy shifts and the pace of CGT product approvals. For a deeper, data-driven view of BLFS’s valuation dynamics, a quick look at ValueRay’s analyst framework can surface the most material risk-adjusted upside scenarios.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -3.21m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.21 > 1.0 |
| NWC/Revenue: 134.3% < 20% (prev 66.45%; Δ 67.90% < -1%) |
| CFO/TA 0.04 > 3% & CFO 16.8m > Net Income -3.21m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.7m) vs 12m ago 5.52% < -2% |
| Gross Margin: 48.48% > 18% (prev 0.57%; Δ 4791 % > 0.5%) |
| Asset Turnover: 19.13% > 50% (prev 22.56%; Δ -3.43% > 0%) |
| Interest Coverage Ratio: -9.92 > 6 (EBITDA TTM -4.87m / Interest Expense TTM 1.08m) |
Altman Z'' -11.04
| A: 0.25 (Total Current Assets 126.6m - Total Current Liabilities 27.1m) / Total Assets 392.1m |
| B: -0.89 (Retained Earnings -350.8m / Total Assets 392.1m) |
| C: -0.03 (EBIT TTM -10.7m / Avg Total Assets 386.9m) |
| D: -9.14 (Book Value of Equity -350.6m / Total Liabilities 38.3m) |
| Altman-Z'' Score: -11.04 = D |
Beneish M -3.30
| DSRI: 0.70 (Receivables 10.8m/17.9m, Revenue 74.0m/86.1m) |
| GMI: 1.18 (GM 48.48% / 57.35%) |
| AQI: 0.92 (AQ_t 0.63 / AQ_t-1 0.68) |
| SGI: 0.86 (Revenue 74.0m / 86.1m) |
| TATA: -0.05 (NI -3.21m - CFO 16.8m) / TA 392.1m) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of BLFS shares?
Over the past week, the price has changed by +2.89%, over one month by -14.88%, over three months by -16.99% and over the past year by -14.36%.
Is BLFS a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BLFS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.4 | 44.6% |
| Analysts Target Price | 32.4 | 44.6% |
| ValueRay Target Price | 22.3 | -0.7% |
BLFS Fundamental Data Overview February 03, 2026
P/S = 10.4812
P/B = 3.0734
P/EG = 65.3833
Revenue TTM = 74.0m USD
EBIT TTM = -10.7m USD
EBITDA TTM = -4.87m USD
Long Term Debt = 5.00m USD (from longTermDebt, last fiscal year)
Short Term Debt = 9.67m USD (from shortTermDebt, last quarter)
Debt = 20.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.80m USD (from netDebt column, last quarter)
Enterprise Value = 991.4m USD (1.05b + Debt 20.7m - CCE 79.0m)
Interest Coverage Ratio = -9.92 (Ebit TTM -10.7m / Interest Expense TTM 1.08m)
EV/FCF = 93.86x (Enterprise Value 991.4m / FCF TTM 10.6m)
FCF Yield = 1.07% (FCF TTM 10.6m / Enterprise Value 991.4m)
FCF Margin = 14.27% (FCF TTM 10.6m / Revenue TTM 74.0m)
Net Margin = -4.33% (Net Income TTM -3.21m / Revenue TTM 74.0m)
Gross Margin = 48.48% ((Revenue TTM 74.0m - Cost of Revenue TTM 38.1m) / Revenue TTM)
Gross Margin QoQ = 66.91% (prev 64.64%)
Tobins Q-Ratio = 2.53 (Enterprise Value 991.4m / Total Assets 392.1m)
Interest Expense / Debt = 2.46% (Interest Expense 508.0k / Debt 20.7m)
Taxrate = 11.66% (82.0k / 703.0k)
NOPAT = -9.43m (EBIT -10.7m * (1 - 11.66%)) [loss with tax shield]
Current Ratio = 4.66 (Total Current Assets 126.6m / Total Current Liabilities 27.1m)
Debt / Equity = 0.06 (Debt 20.7m / totalStockholderEquity, last quarter 353.7m)
Debt / EBITDA = 1.81 (negative EBITDA) (Net Debt -8.80m / EBITDA -4.87m)
Debt / FCF = -0.83 (Net Debt -8.80m / FCF TTM 10.6m)
Total Stockholder Equity = 350.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.83% (Net Income -3.21m / Total Assets 392.1m)
RoE = -0.91% (Net Income TTM -3.21m / Total Stockholder Equity 350.6m)
RoCE = -3.00% (EBIT -10.7m / Capital Employed (Equity 350.6m + L.T.Debt 5.00m))
RoIC = -2.60% (negative operating profit) (NOPAT -9.43m / Invested Capital 362.2m)
WACC = 10.60% (E(1.05b)/V(1.07b) * Re(10.77%) + D(20.7m)/V(1.07b) * Rd(2.46%) * (1-Tc(0.12)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.26%
[DCF Debug] Terminal Value 59.48% ; FCFF base≈8.60m ; Y1≈5.64m ; Y5≈2.58m
Fair Price DCF = 0.91 (EV 34.9m - Net Debt -8.80m = Equity 43.7m / Shares 48.1m; r=10.60% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 40.16 | EPS CAGR: 4.26% | SUE: 0.02 | # QB: 0
Revenue Correlation: -36.53 | Revenue CAGR: -7.31% | SUE: 0.32 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.16 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+100.0% | Growth Revenue=+16.0%